News >

Ibrutinib, Venetoclax, and Obinutuzumab Triplet Safe, Effective as Initial CLL Therapy

Angelica Welch
Published: Friday, Mar 16, 2018

Kerry A. Rogers, MD

Kerry A. Rogers, MD
The regimen of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) can be safely given as initial therapy for chronic lymphocytic leukemia (CLL), according to preliminary results of a phase II trial of treatment-naïve patients.

, Rogers, assistant professor of internal medicine in the Division of Hematology at The Ohio State University Comprehensive Cancer Center, discussed the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with CLL.

OncLive: Can you discuss the initial results of the phase II treatment-naïve cohort?

Rogers: This phase Ib/II study of obinutuzumab, ibrutinib, and venetoclax in CLL is a way to study a chemotherapy-free combination. Generally, combination treatment in CLL has a very long tradition of success, including combinations with chemotherapy and CD20-targeted monoclonal antibodies, leading to very high rates of durable response. However, the side effects of chemotherapy are very difficult for a lot of patients, and there are some long-term side effects.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication